An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects With BRAF V600 Mutation Positive Tumours
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Midazolam; Rosuvastatin
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 23 Sep 2016 Status changed from recruiting to completed.
- 28 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov record.